- Home
- UNCY vs VRCA Comparison
UNCY vs VRCA Comparison
Compare UNCY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | VRCA |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 87.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UNCY | VRCA |
|---|---|---|
| Price | $6.42 | $4.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $44.50 | $17.00 |
| AVG Volume (30 Days) | ★ 424.0K | 117.8K |
| Earning Date | 05-13-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $675,000.00 | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $103.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.45 | $0.39 |
| 52 Week High | $7.57 | $9.82 |
Technical Indicators
Market Signals| Indicator | UNCY | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 30.77 |
| Support Level | $5.90 | $3.96 |
| Resistance Level | $6.82 | $4.87 |
| Average True Range (ATR) | 0.30 | 0.61 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 11.45 | 10.15 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.